Nymox Pharmaceutical Corporation (NYMX) Stock Analysis
DELISTED 2023
What happened to Nymox Pharmaceutical Corporation (NYMX) stock?
Nymox Pharmaceutical Corporation (NYMX) no longer trades on public markets. It was delisted in July 2023. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- July 2023
- Last recorded price (historical):
- $0.1999 (last quote on record before the July 2023 delisting; historical, not a current quote)
Market cap $18.2M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Nymox Pharmaceutical Corporation (NYMX). Nymox Pharmaceutical Corporation is a biopharmaceutical company focused on developing treatments for aging-related conditions. Their lead drug candidate, Fexapotide Triflutate, targets benign prostatic hyperplasia and other indications.
Last analyzed: May 5, 2026Nymox Pharmaceutical Corporation (NYMX) Healthcare & Pipeline Overview
More about this archive record
Can I still buy NYMX shares?
No. NYMX stopped trading on public markets in July 2023, so the shares are not available through a broker. Anything you see quoted for NYMX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before NYMX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Nymox Pharmaceutical Corporation. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.